Comparing CardioGenics (OTCMKTS:CGNH) & LENSAR (NASDAQ:LNSR)

CardioGenics (OTCMKTS:CGNH) and LENSAR (NASDAQ:LNSR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Volatility & Risk

CardioGenics has a beta of 2.54, suggesting that its stock price is 154% more volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Profitability

This table compares CardioGenics and LENSAR’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CardioGenics	N/A	N/A	N/A
LENSAR	-87.12%	N/A	-73.64%

Earnings & Valuation

This table compares CardioGenics and LENSAR”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CardioGenics	N/A	N/A	N/A	N/A	N/A
LENSAR	$53.49 million	2.59	-$31.40 million	($4.39)	-2.64

CardioGenics has higher earnings, but lower revenue than LENSAR.

Institutional and Insider Ownership

40.2% of LENSAR shares are held by institutional investors. 41.4% of CardioGenics shares are held by insiders. Comparatively, 66.0% of LENSAR shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for CardioGenics and LENSAR, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CardioGenics	0	0	0	0	0.00
LENSAR	1	2	0	0	1.67

LENSAR has a consensus target price of $15.00, suggesting a potential upside of 29.20%. Given LENSAR’s stronger consensus rating and higher possible upside, analysts plainly believe LENSAR is more favorable than CardioGenics.

Summary

LENSAR beats CardioGenics on 5 of the 8 factors compared between the two stocks.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.

About LENSAR

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.